Ignite Creation Date:
2025-12-24 @ 9:20 PM
Ignite Modification Date:
2025-12-25 @ 7:07 PM
Study NCT ID:
NCT01079104
Status:
TERMINATED
Last Update Posted:
2019-07-09
First Post:
2010-03-01
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units
Sponsor:
Hepa Wash GmbH
Organization:
Study Overview
Official Title:
Hepa Wash Treatment of Patients With Hepatic Dysfunction in Intensive Care Units
Status:
TERMINATED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The foundations of our pilotstudy planning has changed.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HEPATICUS-2
Brief Summary:
Patients with hepatic dysfunction are known to have a high mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with hepatic dysfunction in the intensive care unit.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: